← Eichor
Study identifier: NCT07064005 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Condition: Parkinsons Disease (PD)  ·  Sponsor: Pravat Mandal

PhasePhase 1
Planned participants12
Who can joinAll sexes, 50 Years to 80 Years
Healthy volunteersNo

About this study

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

This description comes directly from the study's public registry record.

Talk to the study team

Pravat K MANDAL, PHD  ·  4126999561  ·  mandalpk@pitt.edu

Nazia Pillar, M.S  ·  878-670-3123  ·  naa430@pitt.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UPMC Presbyterian HospitalPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07064005